ArticlePharmacogenomics2016
Patient experiences with pharmacogenetic testing in a primary care setting.
Article in Pharmacogenomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of consumers' knowledge, attitudes and experiences of primary health professionals' role in genomic medicine.European journal of human genetics : EJHG · 2025Pooled it
- Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.Clinical pharmacology and therapeutics · 2019Pooled it
- A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics.The pharmacogenomics journal · 2026Trial
- Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes.Clinical pharmacology and therapeutics · 2025Trial
- Design and implementation of PharMe: a mobile application to return pharmacogenomic test results to patients.JAMIA open · 2026Article
- Article
- Knowledge, attitudes, and perceptions of pharmacogenetic testing in swiss community pharmacies: a mixed-methods study among physicians, pharmacists, and the general public.Frontiers in pharmacology · 2026Article
- The aspiration of precision glucocorticoid pharmacotherapy in immune-mediated diseases: where do we stand in integrating pharmacogenomics and biomarkers for individualized treatment?Frontiers in immunology · 2026Review
- Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.Clinical pharmacology and therapeutics · 2026Article
- Cancer patients' perspectives and practices regarding pharmacogenomic testing and its cost.Frontiers in pharmacology · 2026Article
- Assessing the views and opinions of psychiatric patients receiving genome-guided treatment within the scope of the PREPARE preemptive pharmacogenomics clinical study.Frontiers in pharmacology · 2025Article
- Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder.Frontiers in pharmacology · 2024Article
- Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.Clinical and translational science · 2023Article
- Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service.International journal of clinical pharmacy · 2023Article
- Patient understanding of pharmacogenomic test results in clinical care.Patient education and counseling · 2023Article
- Intersection and Considerations for Patient-Centered Care, Patient Experience, and Medication Experience in Pharmacogenomics.Pharmacy (Basel, Switzerland) · 2023Review
- How Pharmacogenomics Informs and Influences the Medication Experience.Innovations in pharmacy · 2023Article
- Public perceptions of pharmacogenomic services in Ireland - Are people with chronic disease more likely to want service availability than those without? A questionnaire study.Exploratory research in clinical and social pharmacy · 2022Article
- Development and Validation of the Minnesota Assessment of Pharmacogenomic Literacy (MAPL).Journal of personalized medicine · 2022Article
- Pharmacogenetic testing among patients with depression in a US managed care population.Clinical and translational science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimTo investigate patient experiences with pharmacogenetic (PGx) testing.
methodsPatients were offered PGx testing through a study on pharmacist-assisted delivery of PGx testing and invited to complete pre- and post-testing surveys about their experience.
resultsOf 63 patients tested, 17 completed the baseline survey (27%). Interest in testing was mostly impacted by desire to inform selection of best treatment (n = 13). Seven of 12 patients that completed the follow-up survey indicated that their provider discussed the test result with them. Five patients understood their test result very or somewhat well. All would be likely to have PGx testing again.
conclusionPatients perceived PGx testing to be useful, though more effort may be needed to improve patient-provider communication of test results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.